

11-13-00

A

Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL636735402US  
Date of Deposit November 9, 2000

Sir:

This is a request for filing an application under 37 C.F.R. 1.53(b) of

Applicant: Bisgård-Frantzen et al

Title: Fungamyl-like Alpha-Amylase Variants

37 pages of specification 0 sheets of Formal Drawings

3 sheets of Declaration and Power of Attorney

1 page of Abstract 5 pages of Sequence Listing

[x] The filing fee is calculated as follows:

Basic Fee: \$710.00

Total Claims:  $19 - 20 = 0 \times 18 =$  \$0

Independent Claims:  $2 - 3 = 0 \times 80 =$  \$0


Total Fee: \$710.00

Priority of Danish application No. PA 1999 01617, filed on November 10, 1999, is claimed under 35 U.S.C. 119.

Priority of U.S. provisional application No. 60/165786, filed on November 16, 1999, is claimed under 35 U.S.C. 119.

Address all future communications to Jason I. Garbell, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.


Please charge the required fee, estimated to be \$710, to Novo Nordisk of North



America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 9, 2000

  
\_\_\_\_\_  
Jason I. Garbell, Esquire, Reg. No. 44116  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE



Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
Title: Fungamyl-like Alpha-Amylase Variants  
Applicants: Bisgård-Frantzen et al

Sir:

Express Mail Label No.

Date of Deposit: November 9, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Kelley O'Patry

(Name of person mailing paper(s) or fee)

K. O'Patry

(Signature of person mailing paper(s) or fee)


Mailing Address:

Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123

America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 9, 2000

  
\_\_\_\_\_  
Jason I. Garbell, Esquire, Reg. No. 44116  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgård-Frantzen et al

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 9, 2000

Examiner: To Be Assigned

For: Fungamyl-like Alpha-Amylase Variants

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

**IN THE SPECIFICATION:**

At page 1, after the title, insert

**--CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims priority under 35 U.S.C. 119 of Danish application PA 1999 01617, filed November 10, 1999, and of U.S. Provisional Application no. 60/165786, filed November 16, 1999, the contents of which are fully incorporated herein by reference.--

**IN THE CLAIMS:**

Please cancel Claims 1-30 without prejudice or disclaimer and add the following new Claims:

31. A variant of a parent Fungamyl-like alpha-amylase, comprising an alteration at one or more regions selected from the group consisting of:

Region 98-110,

Region 150-160,

Region 161-167,

Region 280-288,

Region 448-455, and

Region 468-475;

wherein (a) the alteration(s) are independently

(i) an insertion of an amino acid downstream of the amino acid which occupies the position,

(ii) a deletion of the amino acid which occupies the position, or

(iii) a substitution of the amino acid which occupies the position with a different amino acid,

(b) the variant has alpha-amylase activity and (c) each region or position corresponds to a region position of the amino acid sequence of the parent Fungamyl-like alpha-amylase having the amino acid sequence of SEQ ID NO: 2.

32. The variant of claim 31, wherein the variant includes the following substitution: Q153S.

33. The variant of claim 31, wherein the variant has improved thermostability and/or increased stability at acidic pH.

34. A DNA construct comprising a DNA sequence encoding the variant of claim 31.

35. A recombinant expression vector comprising a DNA construct according to claim 34.

36. A cell which is transformed with a DNA construct according to claim 34.

37. A cell according to claim 36, wherein the cell is a microorganism.

38. The cell according to claim 37, wherein the cell is a protease deficient strain of *Aspergillus*.

39. A composition for producing high maltose syrup comprising the variant of claim 31.


40. A dough improving composition, comprising the variant of claim 31.
41. A brewing composition, comprising the variant of claim 31.
42. The brewing composition of claim 41, further comprising at least one enzyme selected from the group consisting of beta-amylase and isoamylase enzymes.
43. A composition for producing alcohol, comprising the variant of claim 31.
44. A process of liquefying starch, wherein the variant of claim 31 is used for treating starch.
45. A process of producing high maltose syrups, wherein the variant of claim 31 is used for liquefying starch.
46. A brewing process, wherein the variant of claim 31 is added during fermentation of wort.
47. An alcohol production process, wherein the variant of claim 31 is used for liquefying starch .
48. The variant of claim 31 wherein said variant is immobilized.
49. A method for generating an alpha-amylase variant of a parent Fungamyl-like alpha-amylase, which variant has increased thermostability relative to the parent, the method comprising:
- (a) subjecting a DNA sequence encoding the parent Fungamyl-like alpha-amylase to random mutagenesis,
  - (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and
  - (c) screening for host cells expressing a mutated alpha-amylase which has improved thermostability at acidic pH relative to the parent Fungamyl-like alpha-amylase.

## REMARKS

This amendment is submitted to remove multiple dependency and to place the claims in a condition suitable for United States Patent practice. There is no new matter added, and entry of the amendment is respectfully requested.

Respectfully submitted,

Date: November 9, 2000

  
\_\_\_\_\_  
Jason Garbell, Esquire, Reg. No. 44116  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



## TITLE: Fungamyl-like Alpha-Amylase Variants

## FIELD OF THE INVENTION

The present invention relates to alpha-amylase variants  
5 (mutants) of Fungamyl™-like alpha-amylases, in particular with improved thermal stability at acidic pH. The invention also relates to the use of such variants.

## BACKGROUND OF THE INVENTION

10 Alpha-Amylases (alpha-1,4-glucan-4-glucanohydrolases, EC. 3.2.1.1) constitute a group of enzymes which catalyze hydrolysis of starch and other linear and branched 1,4-glucosidic oligo- and polysaccharides.

There is a very extensive body of patent and scientific  
15 literature relating to this industrially very important class of enzymes. A number of alpha-amylase referred to as "Termamyl®-like alpha-amylases" and variants thereof are known from, e.g., WO 90/11352, WO 95/10603, WO 95/26397, WO 96/23873 and WO 96/23874. Termamyl-like alpha-amylases are very thermostable and  
20 therefore suitable for processes carried out at high temperatures such as starch liquefaction in dextrose production processes.

Another group of alpha-amylases are referred to as  
"Fungamyl™-like alpha-amylases", which are alpha-amylases related to the alpha-amylase derived from *Aspergillus oryzae* (and  
25 shown in SEQ ID NO: 1). These Fungamyl-like alpha-amylases have a relatively low thermostability (the commercial product sold under the tradename FUNGAMYL™ by Novo Nordisk, Denmark, has a optimum around 55°C) and is therefore not suitable for processes carried out at high temperatures. Fungamyl-like alpha-amylases are today  
30 used for making syrups for, e.g., the brewing industry. Such processes are operated at around 60°C resulting in that usually in the range of double the enzyme dosage must be used to compensate for the low thermostability. Further, at 55°C infection problems may occur.

35 As such processes today furthermore are carried out at a pH of 5.5, instead of, e.g., pH 4.5, pH adjustment and addition of Sodium to the syrups are necessitated.

Therefore, it would be advantageous to provide a Fungamyl-like alpha-amylase with increased thermostability preferably at

an acidic pH.

#### BRIEF DISCLOSURE OF THE INVENTION

The object of the present invention is to provide Fungamyl-  
5 like alpha-amylase variant, in particular with improved  
thermostability especially at acidic pH.

The term "an alpha-amylase variant with improved  
thermostability" means in the context of the present invention  
an alpha-amylase variant, which has a higher thermostability than  
10 corresponding parent alpha-amylases. The determination of  
thermostability is described below in the Materials and Method  
section.

The inventors have provided improved Fungamyl-like alpha-  
amylase variants as will be described further below.

15

#### DETAILED DISCLOSURE OF THE INVENTION

A goal of the work underlying the present invention was to  
improve the thermal stability, in particular at acidic pH of  
Fungamyl-like alpha-amylases.

20

#### Identifying positions and/or regions to be mutated to obtain improved thermostability

Molecular dynamics (MD) simulations indicate the mobility of  
the amino acids in the protein structure (see McCammon, JA and  
25 Harvey, SC., (1987), "Dynamics of proteins and nucleic acids".  
Cambridge University Press.). Such protein dynamics are often  
compared to the crystallographic B-factors (see Stout, GH and  
Jensen, LH, (1989), "X-ray structure determination", Wiley) or  
the B-factors themselves. By running the MD simulation at  
30 different protonation states of the titrateable residues, the pH  
related mobility of residues are simulated. Regions having the  
highest mobility or flexibility (here isotropic fluctuations) are  
selected for random mutagenesis. It is here understood that the  
high mobility found in certain areas of the protein, can be  
35 thermally improved by substituting residues in these residues.  
The substitutions are directed against residues that have bigger  
side-chains and/or which have capability of forming improved  
contacts to residues in the near environment. The parent  
Fungamyl® alpha-amylase backbone shown in SEQ ID NO: 2 derived  
40 from *Aspergillus oryzae* was used for the MD simulation.

Regions found by Molecular dynamics (MD) simulations or B factor examination (as enclosed to the Protein Data Base (PDB) (www.rcsb.org) file 6TAA (Swift, H. J., Brady, L., Derewenda, Z. S., Dodson, E. J., Dodson, G. G., Turkenburg, J. P., Wilkinson, A. J.: Structure and molecular model refinement of *Aspergillus oryzae* (TAKA) alpha-amylase: an application of the simulated-annealing method. *Acta Crystallogr B* 47 pp. 535 (1991)) to be suitable for mutation when wanting to obtain, in particular increased thermal stability are the following:

- 10 Region 98-110,
- Region 150-160,
- Region 161-167,
- Region 280-288,
- Region 448-455,
- 15 Region 468-475.

The above regions are show to be flexible. Making said regions more rigid would make the molecule more thermostable.

- Accordingly, in a first aspect the present invention relates to a variant of a parent Fungamyl-like alpha-amylase comprising one or more mutations in the regions and positions described further below.

#### Nomenclature

- In the present description and claims, the conventional one-letter and three-letter codes for amino acid residues are used. For ease of reference, alpha-amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s):position(s):substituted amino acid(s)

- According to this nomenclature, for instance the substitution of alanine for asparagine in position 30 is shown as:

Ala30Asn or A30N

a deletion of alanine in the same position is shown as:

Ala30\* or A30\*

- and insertion of an additional amino acid residue, such as lysine, is shown as:

Ala30AlaLys or A30AK

A deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)\* or  $\Delta$ (A30-N33).

Where a specific alpha-amylase contains a "deletion" in comparison with other alpha-amylases and an insertion is made in such a position this is indicated as:

\*36Asp or \*36D

5 for insertion of an aspartic acid in position 36

Multiple mutations are separated by plus signs, i.e.:

Ala30Asp + Glu34Ser or A30N+E34S

representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine,

10 respectively. Multiple mutations may also be separated as follows, i.e., meaning the same as the plus sign:

Ala30Asp/Glu34Ser or A30N/E34S

When one or more alternative amino acid residues may be inserted in a given position it is indicated as

15 A30N,E or

A30N or A30E

Furthermore, when a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the position. Thus, for instance, when a modification of an alanine (A) in position 30 is mentioned, but not specified, or specified as "A30X", it is to be understood that the alanine may be deleted or substituted for any other amino acid, i.e., any one of: R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

#### Fungamyl-like alpha-amylases

Parent Fungamyl-like alpha-amylase are according to the present invention enzymes with alpha-amylase activity which either have at least 60%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90%, even more preferably at least 93%, even more preferably at least 95%, even more preferably at least 97%, even more preferably at least 99% identity to the DNA sequence shown in SEQ ID NO: 1 encoding the alpha-amylase and/or the mature part of the alpha-amylase protein sequence shown in SEQ ID NO: 2 and/or structurally resembles the three-dimensional structure of the FUNGAMYL® alpha-amylase shown in SEQ ID NOS: 1 and 2, and further disclosed in the Protein Data Base (PDB)(www.rcsb.org) file 6TAA (Swift, H. J., Brady, L., Derewenda, Z. S., Dodson, E. J., Dodson, G. G.,

Turkenburg, J. P., Wilkinson, A. J.: Structure and molecular model refinement of *Aspergillus oryzae* (TAKA) alpha-amylase: an application of the simulated-annealing method. *Acta Crystallogr B* 47 pp. 535 (1991) and/or is encoded by a DNA sequence, which hybridizes to the part of the DNA sequence shown in SEQ ID NO: 1 encoding the mature part of the alpha-amylase shown in SEQ ID NO: 2 of the present specification.

Specific examples of such alpha-amylases covered by the definition "Fungamyl-like alpha-amylases" include the *Aspergillus oryzae* TAKA alpha-amylase (EP 238 023) and shown in SEQ ID NO: 2, and the *A. niger* alpha-amylase disclosed in EP 383,779 B2 (section [0037] (see also the cloning of the *A. niger* gene in Example 1).

In an embodiment the Fungamyl-like alpha-amylase is derived from a fungal organism, in particular of the genus *Aspergillus*, in particular *A. oryzae* or *A. niger*.

#### Commercially available parent Fungamyl-like alpha-amylases

Commercially available parent Fungamyl-like alpha-amylases include Fungamyl® (from Novo Nordisk, Denmark). Fungamyl® is a fungal alpha-amylase obtained from a selected strain of *Aspergillus oryzae*. In the starch industry, Fungamyl® is used for production of high maltose syrups, 45-60% maltose (2-7% glucose) or high conversion syrups, DE 60-70, 35-43% glucose, 30-37% maltose. Other commercial fungal alpha-amylases include Clarase™ (from Genencor Int., USA) derived from *Aspergillus oryzae*; and Maltamyl™ (from Enzyme Biosystems) derived from *Aspergillus niger*.

In the brewing industry, FUNGAMYL® (and similar products) is added during fermentation in order to increase fermentability of the wort.

In the alcohol industry, FUNGAMYL® may be used for liquefaction of starch in a distillery mash if the existing equipment favors low-temperature liquefaction (55-60°C). FUNGAMYL® (and similar products) is also used for baking and can be used for all types of bread and baked products. For instance FUNGAMYL® improves the dough stability, result in greater bread volume, improves crumb softness and give the crust a darker

color.

Alpha-amylase variants of the invention

In the first aspect the invention relates to a variant of a  
5 parent Fungamyl-like alpha-amylase comprising one or more  
mutation(s) in the following positions(s) or region(s) in the  
amino acid sequence shown in NO: 2:

Region 98-110,

Region 150-160,

10 Region 161-167;

Region 280-288,

Region 448-455,

Region 468-475, and/or in a corresponding position or region in a  
homologous Fungamyl-like alpha-amylase which displays at least

15 60% identity with the amino acid sequences shown in SEQ ID NO: 2.

In an embodiment the region mutated is Region 98-110.

In an embodiment the region mutated is Region 98-110, more  
specifically one or more of the following positions:  
98,99,100,101,102,103,104,105,106,107,108,109,110.

20 Specific substitutions are

98X, preferably T;

99X, preferably T;

100F,Y,W,I,M; preferably Y;

101R;

25 102S,T,V;

103I,F,V, preferably I;

104T,V,I;

105X, preferably A;

106V,L,N,D,Q,E, preferably V;

30 107V,I,M;

108Y,R,K;

109D,N,Q;

110Q.

In an embodiment the region mutated is Region 150-160, more  
35 specifically one or more of the following positions:  
150,151,152,153,154,155,156,157,158,159,160.

Specific substitutions are

151Y,Q,L,I,R, preferably Y;

152V,L;

40 153T,N,S, preferably S;

154L,Y,V,T,S, preferably L;

155F,N,L;

156X, preferably D,N,S,T;

157S,T,N;

5 158E,Y

159X, preferably S,A;

160X, preferably N;

In an embodiment the region mutated is Region 161-167, more specifically one or more of the following positions: 161, 162,

10 163, 164, 165, 166, 167.

Specific substitutions are

161I,S,T;

162D,N,Q,Y;

163E,Q,N;

15 166V,F,Y,I,S,T,preferably V,F,Y;

167A;

In an embodiment the region mutated is Region 280-288, more specifically one or more of the following positions: 280,281,282,283,284,285,286,287,288.

20 Specific substitutions are

280Q,Y,R;

281X, preferably T,A;

282X, preferably S,T;

285L,N;

25 286X, preferably D;

287V,S,A;

288N,F,Y,E,D, preferably N;

In an embodiment the region mutated is Region 448-455 more specifically one or more of the following positions:

30 448,449,450,451,452,453,454,455.

Specific substitutions are:

448X, preferably A,L,Y,S,T;

449x, preferably L,V,S,T;

450I,T,L;

35 452I,L;

454I,L;

455D,E,S,T.

In an embodiment the region mutated is Region 468-475 more specifically one or more of the following positions:

40 468,469,470,471,472,473,474,475.

Specific substitutions are:

468F, Y, H;

469E, D, Q, N;

470X, preferably A, S, T;

5 471N, T, K, R, F, Y preferably N, T, Y;

472R;

473L, N, Y;

475X, preferably T, R.

#### 10 **Improved stability at acidic pH**

One object of the invention is to make the Fungamyl-like alpha-amylase more acidic in comparison to the parent alpha-amylase (i.e., corresponding un-mutated alpha-amylase).

15 That a Fungamyl-like alpha-amylase variant is more acidic than the parent Fungamyl-like alpha-amylase means that the stability at acidic pH is higher than that for the corresponding parent alpha-amylase. That the amylase is more acidic may be determined as described in the "Materials & Methods" section.

20 The term "acidic pH" means at least in the context of the present invention a pH in the range from 4-6, such as 4-5, in particular 4.2-4.7.

Providing more acidic fungal alpha-amylases are desired, because it opens up for the possibility of using the fungal alpha-amylase variant together with or simultaneously with a  
25 suitable glucoamylase, e.g., during the (dextrinization) saccharification step in starch processes.

#### **Thermal stability**

One object of the invention is to provide a more  
30 thermostable Fungamyl-like alpha-amylase.

That a Fungamyl-like alpha-amylase variant is more thermostable than the parent Fungamyl-like alpha-amylase means that the temperature optimum has been pushed towards a higher temperature. That the amylase is more thermostable may be  
35 determined as described in the "Materials & Methods" section.

Providing more thermostable fungal alpha-amylases is desired because it renders a more efficient and/or faster liquefaction step possible. Further, the liquefaction temperature is less sensitive and may even be increased (i.e.,  
40 less cooling necessary. Further, the risk of infection is also



reduced.

It is to be understood that variants of the invention may have both a more stable at acidic pH and be more thermostable, in particular at acidic pH.

5

### **Homology (Identity)**

The homology (identity) referred to above of the parent alpha-amylase is determined as the degree of identity between two protein or DNA sequences indicating a derivation of the first sequence from the second. The homology (identity) may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, p. 443-453). The (default) GAP creation penalty is 5.0 and the GAP extension penalty of 0.3, respectively, for nucleic acidic sequence comparison; and (default) GAP creation penalty is 3.0 and GAP extension penalty of 0.1, respectively, for protein sequence comparison. GAP uses the method of Needleman and Wunsch, (1970), J.Mol. Biol. 48, p.443-453, to make alignments and to calculate the identity.

Using GAP with the above settings for polypeptide or DNA sequence comparison a parent Fungamyl-like alpha-amylase has a degree of identity preferably of at least 60%, such as 70%, at least 80%, at least 90%, more preferably at least 95%, more preferably at least 97%, and most preferably at least 99% with the mature part of the amino acid sequence shown in SEQ ID NO: 2 and encoding part of the DNA sequence shown in SEQ ID NO: 1.

In a preferred embodiment the variant of the invention has improved thermal stability, in particular at acidic pH.

### Hybridisation

Oligonucleotide probes used in the characterisation of the Fungamyl-like alpha-amylase may suitably be prepared on the basis of the full or partial nucleotide or amino acid sequence of the alpha-amylase in question.

Suitable conditions for testing hybridisation involve pre-soaking in 5xSSC and prehybridizing for 1 hour at ~40°C in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium

phosphate, pH 6.8, and 50mg of denatured sonicated calf thymus DNA, followed by hybridisation in the same solution supplemented with 100 mM ATP for 18 hours at 40°C, followed by three times washing of the filter in 2xSSC, 0.2% SDS at 40°C for 30 minutes (low stringency), preferred at 50°C (medium stringency), more preferably at 65°C (high stringency), even more preferably at 75°C (very high stringency). More details about the hybridisation method can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

In the present context, "derived from" is intended not only to indicate an alpha-amylase produced or producible by a strain of the organism in question, but also an alpha-amylase encoded by a DNA sequence isolated from such strain and produced in a host organism transformed with said DNA sequence. Finally, the term is intended to indicate an alpha-amylase, which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the alpha-amylase in question. The term is also intended to indicate that the parent alpha-amylase may be a variant of a naturally occurring alpha-amylase, i.e., a variant, which is the result of a modification (insertion, substitution, deletion) of one or more amino acid residues of the naturally occurring alpha-amylase.

#### **Cloning a DNA sequence encoding an Fungamyl-like alpha-amylase**

**Cloning a DNA sequence encoding an a-amylase** The DNA sequence encoding a parent Fungamyl-like alpha-amylase may be isolated from any cell or microorganism producing alpha-amylases, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the alpha-amylase to be studied. Then, if the amino acid sequence of the alpha-amylase is known, labeled oligonucleotide probes may be synthesized and used to identify alpha-amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known alpha-amylase gene could be used as a probe to identify alpha-amylase-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying alpha-amylase-encoding

clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming alpha-amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for alpha-amylase (*i.e.*, maltose), thereby allowing clones expressing the alpha-amylase to be identified.

Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, *e.g.* the phosphoroamidite method described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p. 1859-1869, or the method described by Matthes et al., (1984), EMBO J. 3, p. 801-805. In the phosphoroamidite method, oligonucleotides are synthesized, *e.g.*, in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al., (1988), Science 239, pp. 487-491.

### Site-directed mutagenesis

Once a Fungamyl-like alpha-amylase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites. In a specific method, a single-stranded gap of DNA, the alpha-amylase-encoding sequence, is created in a vector carrying the alpha-amylase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al., (1984), Biotechnology 2, p. 646-639. US 4,760,025 disclose the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method for introducing mutations into  $\alpha$ -amylase-encoding DNA sequences is described in Nelson and Long, (1989), Analytical Biochemistry 180, p. 147-151. It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.

### Random Mutagenesis

Random mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in question, or within the whole gene.

The random mutagenesis of a DNA sequence encoding a parent glucoamylase may be conveniently performed by use of any method known in the art.

In relation to the above, a further aspect of the present invention relates to a method for generating a variant of a parent Fungamyl-like alpha-amylase, wherein the variant exhibits increased thermal stability, especially at acidic pH, relative to the parent, the method comprising:

(a) subjecting a DNA sequence encoding the parent Fungamyl-like alpha-amylase to random mutagenesis,

(b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and

(c) screening for host cells expressing an alpha-amylase variant which has an altered property (i.e., thermal stability) relative to the parent Fungamyl-like alpha-amylase.

Step (a) of the above method of the invention is preferably performed using doped primers, as described in the working examples herein (vide infra).

For instance, the random mutagenesis may be performed by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the random mutagenesis may be performed by use of any combination of these mutagenizing agents. The mutagenizing agent may, e.g., be one, which induces transitions, transversions, inversions, scrambling, deletions, and/or insertions.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphate (EMS), sodium bisulphite, formic acid, and nucleotide analogues. When such agents are used, the mutagenesis is typically performed by incubating the DNA sequence encoding the parent enzyme to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions for the mutagenesis to take place, and selecting for mutated DNA having the desired properties.

When the mutagenesis is performed by the use of an oligonucleotide, the oligonucleotide may be doped or spiked with the three non-parent nucleotides during the synthesis of the oligonucleotide at the positions, which are to be changed. The doping or spiking may be done so that codons for unwanted amino acids are avoided. The doped or spiked oligonucleotide can be incorporated into the DNA encoding the glucoamylase enzyme by any published technique, using, e.g., PCR, LCR or any DNA polymerase and ligase as deemed appropriate.

Preferably, the doping is carried out using "constant random doping", in which the percentage of wild type and mutation in each position is predefined. Furthermore, the doping may be directed toward a preference for the introduction of certain nucleotides, and thereby a preference for the introduction of one or more specific amino acid residues. The doping may be made, e.g., so as to allow for the introduction of 90% wild type and 10% mutations in each position. An additional consideration in the choice of a doping scheme is based on genetic as well as protein-structural constraints. The doping scheme may be made by using the DOPE program which, *inter alia*, ensures that introduction of stop codons is avoided.

When PCR-generated mutagenesis is used, either a chemically treated or non-treated gene encoding a parent glucoamylase is subjected to PCR under conditions that increase the misincorporation of nucleotides (Deshler 1992; Leung et al., Technique, Vol.1, 1989, pp. 11-15).

A mutator strain of *E. coli* (Fowler et al., Molec. Gen. Genet., 133, 1974, pp. 179-191), *S. cerevisiae* or any other microbial organism may be used for the random mutagenesis of the DNA encoding the glucoamylase by, e.g., transforming a plasmid  
5 containing the parent glycosylase into the mutator strain, growing the mutator strain with the plasmid and isolating the mutated plasmid from the mutator strain. The mutated plasmid may be subsequently transformed into the expression organism.

The DNA sequence to be mutagenized may be conveniently  
10 present in a genomic or cDNA library prepared from an organism expressing the parent glucoamylase. Alternatively, the DNA sequence may be present on a suitable vector such as a plasmid or a bacteriophage, which as such may be incubated with or otherwise exposed to the mutagenising agent. The DNA to be mutagenized may  
15 also be present in a host cell either by being integrated in the genome of said cell or by being present on a vector harboured in the cell. Finally, the DNA to be mutagenized may be in isolated form. It will be understood that the DNA sequence to be subjected to random mutagenesis is preferably a cDNA or a genomic DNA  
20 sequence.

In some cases it may be convenient to amplify the mutated DNA sequence prior to performing the expression step b) or the screening step c). Such amplification may be performed in accordance with methods known in the art, the presently preferred  
25 method being PCR-generated amplification using oligonucleotide primers prepared on the basis of the DNA or amino acid sequence of the parent enzyme.

Subsequent to the incubation with or exposure to the mutagenising agent, the mutated DNA is expressed by culturing a suitable host cell carrying the DNA sequence under conditions allowing expression to take place. The host cell used for this purpose may be one which has been transformed with the mutated DNA sequence, optionally present on a vector, or one which was carried the DNA sequence encoding the parent enzyme during the mutagenesis treatment. Examples of suitable host cells are the following: gram positive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, *Streptomyces lividans* or *Streptomyces murinus*; and gram-negative bacteria such as *E. coli*.

The mutated DNA sequence may further comprise a DNA sequence encoding functions permitting expression of the mutated DNA sequence.

#### 20 **Localized random mutagenesis**

The random mutagenesis may be advantageously localized to a part of the parent alpha-amylase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.

The localized, or region-specific, random mutagenesis is conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known in the art. Alternatively, the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g., by insertion into a suitable vector, and said part may be subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.



Alternative methods for providing variants of the invention include gene shuffling, e.g., as described in WO 95/22625 (from Affymax Technologies N.V.) or in WO 96/00343 (from Novo Nordisk A/S), or other corresponding techniques resulting in a hybrid enzyme comprising the mutation(s), e.g., substitution(s) and/or deletion, in question.

### Expression of Alpha-Amylase Variants

According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

### Expression vector

The recombinant expression vector carrying the DNA sequence encoding an alpha-amylase variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. The vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Examples of suitable expression vectors include pMT838.

### Promoter

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence, which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the DNA sequence encoding an alpha-amylase variant of the invention, especially in a bacterial host, are the promoter of the *lac* operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the promoters of the *Bacillus*

*stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* alpha-amylase (*amyQ*), the promoters of the *Bacillus subtilis* xylA and xylB genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, the TPI (triose phosphate isomerase) promoter from *S. cerevisiae* (Alber et al. (1982), J. Mol. Appl. Genet 1, p. 419-434, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral alpha-amylase, *A. niger* acid stable alpha-amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

### Expression vector

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the alpha-amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g., as described in WO 91/17243.

The procedures used to ligate the DNA construct of the invention encoding a glucoamylase variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory

Manual, 2nd Ed., Cold Spring Harbor, 1989).

### Host Cells

The cell of the invention, either comprising a DNA construct  
5 or an expression vector of the invention as defined above, is  
advantageously used as a host cell in the recombinant production  
of an alpha-amylase variant of the invention. The cell may be  
transformed with the DNA construct of the invention encoding the  
variant, conveniently by integrating the DNA construct (in one or  
10 more copies) in the host chromosome. This integration is  
generally considered to be an advantage as the DNA sequence is  
more likely to be stably maintained in the cell. Integration of  
the DNA constructs into the host chromosome may be performed  
according to conventional methods, e.g., by homologous or  
15 heterologous recombination. Alternatively, the cell may be  
transformed with an expression vector as described above in  
connection with the different types of host cells.

The cell of the invention may be a cell of a higher organism  
such as a mammal or an insect, but is preferably a microbial  
20 cell, e.g., a bacterial or a fungal (including yeast) cell.

Examples of suitable bacteria are Gram-positive bacteria such  
as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*,  
*Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalo-*  
*philus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus*  
25 *circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus*  
*thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*,  
or gram-negative bacteria such as *E.coli*. The transformation of  
the bacteria may, for instance, be effected by protoplast trans-  
formation or by using competent cells in a manner known *per se*.

30 The yeast organism may favorably be selected from a species  
of *Saccharomyces* or *Schizosaccharomyces*, e.g., *Saccharomyces*  
*cerevisiae*.

The host cell may also be a filamentous fungus, e.g., a  
strain belonging to a species of *Aspergillus*, most preferably  
35 *Aspergillus oryzae* or *Aspergillus niger*, or a strain of *Fusarium*,  
such as a strain of *Fusarium oxysporium*, *Fusarium graminearum* (in  
the perfect state named *Gibberella zeae*, previously *Sphaeria*  
*zeae*, synonym with *Gibberella roseum* and *Gibberella roseum* f. sp.

cerealis), or *Fusarium sulphureum* (in the prefect state named *Gibberella puricaridis*, synonym with *Fusarium trichothecioides*, *Fusarium bactridioides*, *Fusarium sambucium*, *Fusarium roseum*, and *Fusarium roseum* var. *graminearum*), *Fusarium cerealis* (synonym  
5 with *Fusarium crockwellense*), or *Fusarium venenatum*.

In a preferred embodiment of the invention the host cell is a protease deficient or protease minus strain. This may for instance be the protease deficient strain of the genus *Aspergillus*, in particular a strain of *A. oryzae*, such as *A.*  
10 *oryzae* JaL125 having the alkaline protease gene named "alp" deleted. This strain is described in WO 97/35956 (Novo Nordisk).

Filamentous fungi cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner  
15 known per se. The use of *Aspergillus* as a host micro-organism is described in EP 238 023 (Novo Nordisk), the contents of which are hereby incorporated by reference.

#### **Method of producing an Alpha-amylase Variant of the invention**

20 In a yet further aspect, the present invention relates to a method of producing an alpha-amylase variant of the invention, which method comprises cultivating a host cell under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

25 The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the alpha-amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g., as  
30 described in catalogues of the American Type Culture Collection).

The alpha-amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous  
35 components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

### Starch conversion

The present invention provides a method of using alpha-amylase variants of the invention for producing glucose or maltose or the like from starch.

5 Generally, the method includes the steps of partially hydrolyzing precursor starch in the presence of alpha-amylase and then further hydrolyzing the release of D-glucose from the non-reducing ends of the starch or related oligo- and polysaccharide molecules in the presence of glucoamylase by cleaving alpha-  
10 (1 $\rightarrow$ 4) and alpha-(1 $\rightarrow$ 6) glucosidic bonds.

The partial hydrolysis of the precursor starch utilizing alpha-amylase provides an initial breakdown of the starch molecules by hydrolyzing internal alpha-(1 $\rightarrow$ 4)-linkages. In commercial applications, the initial hydrolysis using alpha-  
15 amylase is run at a temperature of approximately 105°C. A very high starch concentration is processed, usually 30% to 40% solids. The initial hydrolysis is usually carried out for five minutes at this elevated temperature. The partially hydrolyzed starch can then be transferred to a second tank and incubated for  
20 approximately one hour at a temperature of 85° to 90°C to derive a dextrose equivalent (D.E.) of 10 to 15.

The step of further hydrolyzing the release of D-glucose from the non-reducing ends of the starch or related oligo- and polysaccharides molecules in the presence of glucoamylase is  
25 normally carried out in a separate tank at a reduced temperature between 30° and 60°C. Preferably the temperature of the substrate liquid is dropped to between 55° and 60°C. The pH of the solution is dropped from 6 to 6.5 to a range between 3 and 5.5. Preferably, the pH of the solution is 4 to 4.5. The glucoamylase  
30 is added to the solution and the reaction is carried out for 24-72 hours, preferably 36-48 hours.

By improving the thermo stability of the Fungamyl-like alpha-amylase variant according to the invention said alpha-amylases may be used for starch liquefaction.

35 In an aspect the invention relates to the use of an alpha-amylase variant of the invention in a starch conversion process.

## Brewing

The alpha-amylase variant of the invention may also be used in brewing processes.

### 5 High Maltose syrup production (55% maltose)

A variant of the invention may be used for maltose production. High maltose syrup is typically produced as follows:

#### Production of High Maltose Syrup (containing 50-55% maltose)

10 To produce "High Maltose Syrup" starch is liquefied to DE 10-20. The pH and temperature of the liquefied starch is adjusted to 65°C and to a pH around 5.0, respectively, and is subjected to maltogenic alpha-amylase activity (e.g., *Bacillus*  
15 *stearothermophilus* amylase, such as Maltogenase™ 4000 L, 0.4 l/t DS (Novo Nordisk)), pullulanase activity (e.g., *Bacillus*  
*pullulanase*, such as Promozyme™ 600 L, 0.3 l/t DS (Novo Nordisk)) and alpha-amylase activity (e.g., BAN 240 L or Termamyl™ 120 L, type LS, 0.4 kg/t DS (Novo Nordisk)) for 24-41 hours. The specific process time depends on the desired saccharide spectrum  
20 to be achieved. By increasing the dosage of the maltogenic alpha-amylase and pullulanase the maltose content can be increased.

Alternatively, "High Maltose Syrup" may be produced by first liquefying starch to DE 10-20 and then adjusting the pH and temperature to 55°C and a pH around 5.5, respectively, and  
25 subjecting the liquefied starch to a fungal alpha-amylase activity (e.g., *Bacillus stearothermophilus* amylase, such as Fungamyl™ 800L (Novo Nordisk)) for 22-44 hours. The dosage of fungal alpha-amylase depends on the saccharification time foreseen, e.g., 200 g/t DS for 44 hours and 400 g/t DS for 22  
30 hours.

To produce "High Maltose Syrup" starch with maltose content of 55-65% starch is liquefied to DE 10-20. The pH and temperature of the liquefied starch is adjusted to 60°C and to a pH around 6, respectively, and is subjected to maltogenic alpha-  
35 amylase activity (e.g., Maltogenase™ 4000 L, 0.25-1.0 l/t DS (Novo Nordisk)), and fungal alpha-amylase activity (e.g., *Aspergillus* amylase, such as Fungamyl™ 800 L, 0.4-1.0 kg/t DS (Novo Nordisk) for 24-48 hours.

Alternatively, the liquefied starch may adjusted to a temperature of 65°C and a pH around 5.0 and subjected to maltogenic alpha-amylase activity (e.g., *Bacillus* *stearothermophilus* amylase, such as Maltogenase™ 4000 L, 0.5-1.0 l/t DS), and pullulanase activity (e.g., *Bacillus* pullulanase, such as Promozyme™ 600 L, 0.5-1.0 l/t DS) for 18-42 hours.

According to the invention one or more Fungamyl-like variants of the invention may be used instead of or together with the above mentioned fungal alpha-amylase activity.

10

### **Baking**

The alpha-amylase variant of the invention may also be used in baking processes.

15

### **Use**

In one aspect the invention relates to the used of a variant of the invention for starch conversion, alcohol production, brewing, baking.

20

### **Processes of the invention**

The invention also relates to a process of producing maltose syrup comprising the steps of:

- 1) liquefying starch in the presence of an alpha-amylase;
- 2) dextrinization in the presence of a fungal alpha-amylase variant of the invention; and
- 3) recovery of the syrup; and optional purification of the syrup.

The alpha-amylase used for liquefaction in step 1) may be any alpha-amylase. Preferred alpha-amylase are *Bacillus* alpha-amylases, such as a Termamyl-like alpha-amylase, which including the *B. licheniformis* alpha-amylase (commercially available as Termamyl™ (Novo Nordisk)), the *B. amyloliquefaciens* alpha-amylase (sold as BAN (Novo Nordisk), the *B. stearothermophilus* alpha-amylase (sold as Termamyl™ 120 L type S), The alpha-amylases derived from a strain of the *Bacillus* sp. NCIB 12289, NCIB 12512, NCIB 12513 or DSM 9375, all of which are described in detail in WO 95/26397, and the alpha-amylase described by Tsukamoto et al., Biochemical and Biophysical Research

Communications, 151 (1988), pp. 25-31. Alpha-amylases within the definition of "Termamyl-like alpha-amylase" are defined in for instance WO 96/23874 (Novo Nordisk).

In another aspect the invention relates to a process of  
5 producing maltose comprising the steps of:

- 1)liquefying starch at a temperature of 140-160°C at a pH of 4-6;
- 2)dextrinization at a temperature in the range from 60-95°C, in particular at 65-85°C, such as 70-80°C, at a pH 4-6 in the  
10 presence of a fungal alpha-amylase variant of the invention; and
- 3) recovery of the syrup; and optional purification of the syrup.

In an embodiment of the invention an effective amount of glucoamylase is added in step 2). The syrup will in this  
15 embodiment (including treatment with a glucoamylase) not be maltose syrup, but syrup with a different sugar profile.

The glucoamylase may be an *Aspergillus* glucoamylase, in particular an *Aspergillus niger* glucoamylase.

Alternatively, the process comprising the steps of:

- 20 1)liquefying starch at a temperature of 95-110°C at a pH of 4-6 in the presence of a *Bacillus* alpha-amylase;
- 2)liquefying at a temperature in the range from 70-95°C at a pH 4-6 in the presence of a fungal alpha-amylase variant of the invention, followed by recovery and/or optional purification of  
25 the product obtained.



### Immobilized fungal alpha-amylase variants of the invention

In an aspect the invention relates to an immobilized alpha-amylase variant of the invention. The alpha-amylase variant may  
5 be immobilized using any suitable method known in the art such as method used for glucose isomerase in US patent no. 4,687,742.

### **MATERIALS AND METHODS**

#### **Material:**

##### 10 Enzymes:

FUNGAMYL®: fungal alpha-amylase derived from *Aspergillus oryzae* (available from Novo Nordisk) and shown in SEQ ID NO: 2.

##### Host cell:

15 *A. oryzae* JaL125: *Aspergillus oryzae* IFO 4177 available from Institute for Fermentation, Osaka; 17-25 Juso Hammachi 2-Chome Yodogawa-ku, Osaka, Japan, having the alkaline protease gene named "alp" (described by Murakami K et al., (1991), Agric. Biol. Chem. 55, p. 2807-2811) deleted by a one step gene  
20 replacement method (described by G. May in "Applied Molecular Genetics of Filamentous Fungi" (1992), p. 1-25. Eds. J. R. Kinghorn and G. Turner; Blackie Academic and Professional), using the *A. oryzae* pyrG gene as marker. Strain JaL 125 is further disclosed in WO 97/35956 (Novo Nordisk).

25

##### Micro-organisms:

Strain: *Saccharomyces cerevisiae* YNG318: MAT $\alpha$ leu2- $\Delta$ 2 ura3-52 his4-539 pep4- $\Delta$ 1[cir+]

##### 30 **Methods:**

##### Transformation of *Aspergillus oryzae* (general procedure)

100 ml of YPD (Sherman et al., (1981), Methods in Yeast Genetics, Cold Spring Harbor Laboratory) are inoculated with spores of *A. oryzae* and incubated with shaking for about 24  
35 hours. The mycelium is harvested by filtration through miracloth and washed with 200 ml of 0.6 M MgSO<sub>4</sub>. The mycelium is suspended in 15 ml of 1.2 M MgSO<sub>4</sub>, 10 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 5.8. The suspension is cooled on ice and 1 ml of buffer containing 120 mg of

Novozym™ 234 is added. After 5 min., 1 ml of 12 mg/ml BSA (Sigma type H25) is added and incubation with gentle agitation continued for 1.5-2.5 hours at 37C until a large number of protoplasts is visible in a sample inspected under the microscope.

The suspension is filtered through miracloth, the filtrate transferred to a sterile tube and overlaid with 5 ml of 0.6 M sorbitol, 100 mM Tris-HCl, pH 7.0. Centrifugation is performed for 15 min. at 1000 g and the protoplasts are collected from the top of the MgSO<sub>4</sub> cushion. 2 volumes of STC (1.2 M sorbitol, 10 mM Tris-HCl, pH 7.5, 10 mM CaCl<sub>2</sub>) are added to the protoplast suspension and the mixture is centrifuged for 5 min. at 1000 g. The protoplast pellet is resuspended in 3 ml of STC and repelleted. This is repeated. Finally, the protoplasts are resuspended in 0.2-1 ml of STC.

100 micro liter of protoplast suspension are mixed with 5-25 micro grams of p3SR2 (an *A. nidulans* amdS gene carrying plasmid described in Hynes et al., Mol. and Cel. Biol., Vol. 3, No. 8, 1430-1439, Aug. 1983) in 10 micro liter of STC. The mixture is left at room temperature for 25 minutes 0.2 ml of 60% PEG 4000 (BDH 29576), 10 mM CaCl<sub>2</sub> and 10 mM Tris-HCl, pH 7.5 is added and carefully mixed (twice) and finally 0.85 ml of the same solution are added and carefully mixed. The mixture is left at room temperature for 25 min., spun at 2.500 g for 15 min. and the pellet is resuspended in 2 ml of 1.2M sorbitol. After one more sedimentation the protoplasts are spread on minimal plates (Cove, (1966), Biochem. Biophys. Acta 113, 51-56) containing 1.0 M sucrose, pH 7.0, 10 mM acetamide as nitrogen source and 20 mM CsCl to inhibit background growth. After incubation for 4-7 days at 37C spores are picked, suspended in sterile water and spread for single colonies. This procedure is repeated and spores of a single colony after the second re-isolation are stored as a defined transformant.

### Fed batch fermentation

Fed batch fermentation is performed in a medium comprising maltodextrin as a carbon source, urea as a nitrogen source and yeast extract. The fed batch fermentation is performed by inoculating a shake flask culture of *A. oryzae* host cells in question into a medium comprising 3.5% of the carbon source and 0.5% of the nitrogen source. After 24 hours of cultivation at pH 5.0 and 34°C the continuous supply of additional carbon and nitrogen sources are initiated. The carbon source is kept as the limiting factor and it is secured that oxygen is present in excess. The fed batch cultivation is continued for 4 days, after which the enzymes can be recovered by centrifugation, ultrafiltration, clear filtration and germ filtration. Further purification may be done by anion-exchange chromatographic methods known in the art.

### Purification

The culture broth is filtrated and added ammonium sulphate (AMS) to a concentration of 1.7 M AMS and pH is adjusted to pH 5. Precipitated material is removed by centrifugation on the solution containing alpha-amylase activity is applied on a Toyo Pearl Butyl column previously equilibrated in 1.7 M AMS, 20 mM sodium acetate, pH 5. Unbound material is washed out with the equilibration buffer. Bound proteins are eluted with 10 mM sodium acetate, pH 4.5 using a linear gradient from 1.7 - 0 M AMS over 10 column volumes. Glucoamylase containing fractions are collected and dialysed against 20 mM sodium acetate, pH 4.5.

### Screening for thermostable alpha-amylase variants

The libraries are screened in the thermostable filter assay described below.

### Filter assay for thermostability

Yeast libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany) - and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on SC ura<sup>-</sup>agar plates with 100 micro gram/ml ampicillin at 30°C for at least 72 hrs. The colonies are replica plated to PVDF filters (Immobilon-P, Millipore, Bedford)

activated with methanol for 1 min and subsequently washed in 0.1 M NaAc and then incubated at room temperature for 2 hours. Colonies are washed from PVDF filters with tap water. Each filter sandwiches and PVDF filters are specifically marked with a needle before incubation in order to be able to localise positive variants on the filters after the screening. The PVDF filters with bound variants are transferred to a container with 0.1 M NaAc, pH 4.5 and incubated at 47°C for 15 minutes. The sandwich of cellulose acetate and nitrocellulose filters on SC ura-agar plates are stored at room temperature until use. After incubation, the residual activities are detected on plates containing 5% maltose, 1% agarose, 50 mM NaAc, pH 4.5. The assay plates with PVDF filters are marked the same way as the filter sandwiches and incubated for 2 hrs. at 50°C. After removal of the PVDF filters, the assay plates are stained with Glucose GOD perid (Boehringer Mannheim GmbH, Germany). Variants with residual activity are detected on assay plates as dark green spots on white background. The improved variants are located on the storage plates. Improved variants are re-screened twice under the same conditions as the first screen.

#### Determination of FAU activity

One Fungal Alpha-Amylase Unit (FAU) is defined as the amount of enzyme, which breaks down 5.26 g starch (Merck Amylum solubile Erg. B.6, Batch 9947275) per hour at Novo Nordisk's standard method for determination of alpha-amylase based upon the following standard conditions:

Substrate . . . . . Soluble starch  
 Temperature . . . . . 37°C  
 PH. . . . . 4.7  
 Reaction time . . . . . 7-20 minutes

A detailed description of Novo Nordisk's method is available on request.

#### Determination of acid alpha-amylase activity (AFAU)

Acid alpha-amylase activity is measured in AFAU (Acid Fungal Alpha-amylase Units), which are determined relative to an enzyme standard.

The standard used is AMG 300 L (from Novo Nordiks). The

neutral alpha-amylase in this AMG falls after storage at room temperature for 3 weeks from approx. 1 FAU/mL to below 0.05 FAU/mL.

The acid alpha-amylase activity in this AMG standard is determined in accordance with AF 9 1/3 (Novo method for the determination of fungal alpha-amylase). In this method, 1 FAU is defined as the amount of enzyme, which degrades 5.260 mg starch dry matter per hour under standard conditions.

Iodine forms a blue complex with starch but not with its degradation products. The intensity of colour is therefore directly proportional to the concentration of starch. Amylase activity is determined using reverse colorimetry as a reduction in the concentration of starch under specified analytic conditions.

15	Alpha-amylase
Starch + Iodine	→ Dextrins + Oligosaccharides
	40°C, pH 2.5
Blue/violet	t=23 sec. Decoloration

20 Standard conditions/reaction conditions: (per minute)

Substrate: starch, approx. 0.17 g/L

Buffer: Citrate, approx. 0.03 M

Iodine (I<sub>2</sub>): 0.03 g/L

CaCl<sub>2</sub>: 1.85 mM

25 pH: 2.50 ± 0.05

Incubation temperature: 40°C

Reaction time: 23 seconds

Wavelength: lambda=590nm

Enzyme concentration: 0.025 AFAU/mL

30 Enzyme working range: 0.01-0.04 AFAU/mL

Further details can be found in EB-SM-0259.02/01 available on request from Novo Nordisk, and incorporated by reference.

35 Thermal/pH Stability Determination of Variant of the invention

The thermal stability of variants of the invention is tested using the following method: 950 micro liter 0.1 M Citrate + 4.3 mM Ca<sup>2+</sup> buffer is incubated for 1 hour at 60°C. 50 micro liter enzyme in buffer (4 AFAU/ml) is added. 2 x 40 micro liter

samples are taken at 0 and 60 minutes and chilled on ice. The activity (AFAU/ml) measured before incubation (0 minutes) is used as reference (100%). The decline in percent is calculated as a function of the incubation time.

- 5 To determine the Thermal stability the test is repeated using different temperatures, for instance 50, 60, 70, 80 and 90°C.

To determine the pH stability the test is repeated using different pHs, for instance, pH 2.5; 3; 3.5; 4; 4.5; 5.

### General method for random mutagenesis by use of the DOPE program

The random mutagenesis may be carried out as follows:

1. Select regions of interest for modification in the parent enzyme,

5 2. Decide on mutation sites and non-mutated sites in the selected region,

3. Decide on which kind of mutations should be carried out, e.g. with respect to the desired stability and/or performance of the variant to be constructed,

10 4. Select structurally reasonable mutations,

5. Adjust the residues selected by step 3 with regard to step 4.

6. Analyze by use of a suitable dope algorithm the nucleotide distribution.

15 7. If necessary, adjust the wanted residues to genetic code realism, e.g., taking into account constraints resulting from the genetic code, e.g., in order to avoid introduction of stop codons; the skilled person will be aware that some codon combinations cannot be used in practice and will need to be adapted

20 8. Make primers

9. Perform random mutagenesis by use of the primers

10. Select resulting glucoamylase variants by screening for the desired improved properties.

### Dope algorithm

Suitable dope algorithms for use in step 6 are well known in the art. One such algorithm is described by Tomandl, D. et al., 1997, Journal of Computer-Aided Molecular Design 11:29-38.

30 Another algorithm is DOPE (Jensen, LJ, Andersen, KV, Svendsen, A, and Kretzschmar, T (1998) Nucleic Acids Research 26:697-702).

## **EXAMPLES**

### **Example 1**

#### 35 Construction of variant Q153S

For the construction of variants of the TAKA-amylase enzyme (Fungamyl™ shown in SEQ ID NOS: 1 and 2) the commercial kit, Chameleon double-stranded, site-directed mutagenesis kit is used according to the manufacturer's instructions.

The gene encoding the amylase enzyme in question is in plasmid pTAKA17 (EP 238,023, figure 2 and Example 2). In accordance with the manufacturer's instructions the ScaI site of the Ampicillin gene of pTAKA17 is changed to a MluI site by use  
5 of the following primer:

Primer 7258:

5'p gaa tga ctt ggt tga cgc gtc acc agt cac 3' (SEQ ID NO: 3)

10 The ScaI site in an intron in the Amylase gene is removed using the primer

Primer 1:

5'p ATG GTT CAT TTC AGA ACT GAC ATT GAG TAA (SEQ ID NO: 4)

15 The desired mutation is introduced into the amylase gene in question by addition of an appropriate oligos comprising the desired mutation.

To introduce a mutation such as Q153S an oligo is design:

Primer 2:

20

5'P TTC TGT TTC ATT TCG AAC TAT GAA GAT (SEQ ID NO: 5)

The pTAKA17 vector comprising the amylase gene in question is then used as a template for DNA polymerase, DNA ligase (for  
25 ligation to 5'Phosphate (5'P) on the oligoes), and the oligoes 7258, primer 1 and primer 2.

DNA-prep. are made, and the introduction of the mutation is verified by sequencing.

The DNA prep. is transformed in *Aspergillus oryzae* host  
30 cell as describe in the "Materials & Methods" section and the transformants are screened for amylase activity.



**Example 2**Increased thermo stability

5 The variant constructed in Example 1 is tested for increased thermostability in accordance with the thermo stability determination assay disclosed in the "Materials & Methods" section.

**Example 3**10 Increased acidic stability

The variant constructed in Example 1 is tested for increased stability at acidic pH in accordance with the pH stability determination assay disclosed in the "Materials & Methods" section.

**CLAIMS**

1. A variant of a parent Fungamyl-like alpha-amylase, comprising an alteration at one or more regions selected from the group of:
- 5   Region 98-110,  
     Region 150-160,  
     Region 161-167,  
     Region 280-288,  
     Region 448-455,  
10   Region 468-475.
- wherein (a) the alteration(s) are independently
- (i) an insertion of an amino acid downstream of the amino acid which occupies the position,
- (ii) a deletion of the amino acid which occupies the
- 15   position, or
- (iii) a substitution of the amino acid which occupies the position with a different amino acid,
- (b) the variant has alpha-amylase activity and (c) each region or position corresponds to a region position of the amino acid
- 20   sequence of the parent Fungamyl-like alpha-amylase having the amino acid sequence of SEQ ID NO: 2.
2. The variant of claim 1, wherein the variant is one or more of the following substitution: Q153S.
- 25   3. The variant of claims 1, which variant has improved thermostability and/or increased stability at acidic pH.
4. A DNA construct comprising a DNA sequence encoding an alpha-
- 30   amylase variant of any of claims 1-3.
5. A recombinant expression vector which carries a DNA construct according to claim 4.
- 35   6. A cell which is transformed with a DNA construct according to claim 4 or a vector according to claim 5.
7. A cell according to claim 6, wherein the cell is a microorganism, such as a bacterium or a fungus.

8. The cell according to claim 7, which is a protease deficient strain of *Aspergillus*, in particular *A. oryzae*.

9. A composition for producing high maltose syrup comprising an  
5 Fungamyl-like alpha-amylase variant of claims 1-3.

10. The composition of claim 9, further comprising beta-amylase activity.

10 11. A dough improving composition, comprising an alpha-amylase variant of any of claims 1-3.

12. A brewing composition comprising an alpha-amylase variant of any of claims 1-3.

15 13. The brewing composition of claim 12, further comprising one or ore enzymes selected from the group of beta-amylase and isoamylase.

20 14. A composition for producing alcohol, comprising an alpha-amylase variant of any of claims 1-3.

15 15. A process of liquefying starch, wherein an alpha-amylase variant of claims 1-3 is used for treating starch.

25 16. A process of producing high maltose syrups, wherein an alpha-amylase variant of claims 1-3 is used for liquefying starch.

30 17. A brewing process, wherein an alpha-amylase variant of claims 1-3 is added during fermentation of wort.

18. An alcohol production process, wherein an alpha-amylase variant of claim 1-3 is used for liquefaction starch in a distillery mash.

35 19. A process, wherein a dough product comprising an alpha-amylase variant of claims 1-3 is baked.

20. Use of an alpha-amylase variant of any of claims 1-3 or a

composition of claim 9 for starch liquefaction.

21. Use of an alpha-amylase variant of any of claims 1-3 or a composition of claim 9 for producing alcohol.

5

22. Use of an alpha-amylase variant of any of claims 1-3 or a composition of claim 9 for brewing.

10

23. Use of an alpha-amylase variant of any of claims 1-3 or a composition of claim 9 for baking.

15

24. A method for generating an alpha-amylase variant of a parent Fungamyl-like alpha-amylase, which variant has increased thermostability, in particular at acidic pH relative to the parent, the method comprising:

(a) subjecting a DNA sequence encoding the parent Fungamyl-like alpha-amylase to random mutagenesis,

(b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and

20

(c) screening for host cells expressing a mutated alpha-amylase which has improved thermostability at acidic pH relative to the parent Fungamyl-like alpha-amylase.

25

25. Process for producing a maltose syrup comprising the steps of:

1) liquefying starch in the presence of an alpha-amylase, followed by

2) dextrinization the presence of a fungal alpha-amylase variant of claim 1-3;

30

3) recovery of the syrup; and optional purification.

26. Process for producing syrup, in particular maltose syrup, comprising the steps of:

35

1) liquefying starch at a temperature of 140-160°C at a pH of 4-6, followed by

2) dextrinization at a temperature in the range from 60-95°C at a pH 4-6 in the presence of a fungal alpha-amylase variant of claims 1-3; and

3) recovery of the syrup; and optional purification.

27. The process of claim 26, wherein the liquefying starch is treated at a temperature of 65-85°C, in particular 70-80°C.

5 28. The process of claim 27, wherein an effective amount of glucoamylase is added in step 2).

29. Process for producing maltose syrup, comprising the steps of:

10 1)liquefying starch at a temperature of 95-110°C at a pH of 4-6 in the presence of a *Bacillus* alpha-amylase, followed by

2)dextrinization at a temperature in the range from 60-95°C at a pH 4-6 in the presence of a fungal alpha-amylase variant of claims 1-3; and

15 3) recovery of the syrup; and optional purification.

30. An immobilized variant of claims 1-3.

Title: Fungamyl-like Alpha-Amylase Variants

**ABSTRACT**

The invention relates to a variant of a parent Fungamyl-like  
5 fungal alpha-amylase, which exhibits improved thermal stability  
at acidic pH suitable for, e.g., starch processes.

## SEQUENCE LISTING

&lt;110&gt; Novo Nordiks A/S

5 &lt;120&gt; Fungamyl-like alpha-amylase variants

&lt;130&gt; 5835.204-WO

&lt;160&gt; 5

10 &lt;170&gt; PatentIn version 3.0

&lt;210&gt; 1

&lt;211&gt; 1734

15 &lt;212&gt; DNA

&lt;213&gt; Aspergillus oryzae

&lt;220&gt;

&lt;221&gt; CDS

20 &lt;222&gt; (54)..(1547)

&lt;220&gt;

&lt;221&gt; mat\_peptide

&lt;222&gt; (114)..()

25 &lt;400&gt; 1

tcacatcaag ctctcccttc tctgaacaat aaaccccaca gaaggcattt atg atg 56  
Met  
-20

30 gtc gcg tgg tgg tct cta ttt ctg tac ggc ctt cag gtc gcg gca cct 104  
Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln Val Ala Ala Pro  
-15 -10 -5

35 gct ttg gct gca acg cct gcg gac tgg cga tcg caa tcc att tat ttc 152  
Ala Leu Ala Ala Thr Pro Ala Asp Trp Arg Ser Gln Ser Ile Tyr Phe  
-1 1 5 10

40 ctt ctc acg gat cga ttt gca agg acg gat ggg tcg acg act gcg act 200  
Leu Leu Thr Asp Arg Phe Ala Arg Thr Asp Gly Ser Thr Thr Ala Thr  
15 20 25

45 tgt aat act gcg gat cag aaa tac tgt ggt gga aca tgg cag ggc atc 248  
Cys Asn Thr Ala Asp Gln Lys Tyr Cys Gly Gly Thr Trp Gln Gly Ile  
30 35 40 45

atc gac aag ttg gac tat atc cag gga atg ggc ttc aca gcc atc tgg 296  
Ile Asp Lys Leu Asp Tyr Ile Gln Gly Met Gly Phe Thr Ala Ile Trp  
50 55 60

50 atc acc ccc gtt aca gcc cag ctg ccc cag acc acc gca tat gga gat 344  
Ile Thr Pro Val Thr Ala Gln Leu Pro Gln Thr Thr Ala Tyr Gly Asp  
65 70 75

55 gcc tac cat ggc tac tgg cag cag gat ata tac tct ctg aac gaa aac 392  
Ala Tyr His Gly Tyr Trp Gln Gln Asp Ile Tyr Ser Leu Asn Glu Asn  
80 85 90

60 tac ggc act gca gat gac ttg aag gcg ctc tct tcg gcc ctt cat gag 440  
Tyr Gly Thr Ala Asp Asp Leu Lys Ala Leu Ser Ser Ala Leu His Glu  
95 100 105

agg ggg atg tat ctt atg gtc gat gtg gtt gct aac cat atg ggc tat 488  
Arg Gly Met Tyr Leu Met Val Asp Val Val Ala Asn His Met Gly Tyr  
110 115 120 125

65 gat gga gcg ggt agc tca gtc gat tac agt gtg ttt aaa ccg ttc agt 536  
Asp Gly Ala Gly Ser Ser Val Asp Tyr Ser Val Phe Lys Pro Phe Ser  
130 135 140

70 tcc caa gac tac ttc cac ccg ttc tgt ttc att caa aac tat gaa gat 584

	Ser	Gln	Asp	Tyr 145	Phe	His	Pro	Phe	Cys 150	Phe	Ile	Gln	Asn	Tyr 155	Glu	Asp	
5	cag Gln	act Thr	cag Gln	gtt Val	gag Glu	gat Asp	tgc Cys	tgg Trp	cta Leu	gga Gly	gat Asp	aac Asn	act Thr	gtc Val	tcc Ser	ttg Leu	632
10	cct Pro	gat Asp	ctc Leu	gat Asp	acc Thr	acc Thr	aag Lys	gat Asp	gtg Val	gtc Val	aag Lys	aat Asn	gaa Glu	tgg Trp	tac Tyr	gac Asp	680
15	tgg Trp	gtg Val	gga Gly	tca Ser	ttg Leu	gta Val	tcg Ser	aac Asn	tac Tyr	tcc Ser	att Ile	gac Asp	ggc Gly	ctc Leu	cgt Arg	atc Ile	728
20	gac Asp	aca Thr	gta Val	aaa Lys	cac His	gtc Val	cag Gln	aag Lys	gac Asp	ttc Phe	tgg Trp	ccc Pro	ggg Gly	tac Tyr	aac Asn	aaa Lys	776
25	gcc Ala	gca Ala	ggc Gly	gtg Val	tac Tyr	tgt Cys	atc Ile	ggc Gly	gag Glu	gtg Val	ctc Leu	gac Asp	ggt Gly	gat Asp	ccg Pro	gcc Ala	824
30	tac Tyr	act Thr	tgt Cys	ccc Pro	tac Tyr	cag Gln	aac Asn	gtc Val	atg Met	gac Asp	ggc Gly	gta Val	ctg Leu	aac Asn	tat Tyr	ccc Pro	872
35	att Ile	tac Tyr	tat Tyr	cca Pro	ctc Leu	ctc Leu	aac Asn	gcc Ala	ttc Phe	aag Lys	tca Ser	acc Thr	tcc Ser	ggc Gly	agc Ser	atg Met	920
40	gac Asp	gac Asp	ctc Leu	tac Tyr	aac Asn	atg Met	atc Ile	aac Asn	acc Thr	gtc Val	aaa Lys	tcc Ser	gac Asp	tgt Cys	cca Pro	gac Asp	968
45	tca Ser	aca Thr	ctc Leu	ctg Leu	ggc Gly	aca Thr	ttc Phe	gtc Val	gag Glu	aac Asn	cac His	gac Asp	aac Asn	cca Pro	cgg Arg	ttc Phe	1016
50	gct Ala	tct Ser	tac Tyr	acc Thr	aac Asn	gac Asp	ata Ile	gcc Ala	ctc Leu	gcc Ala	aag Lys	aac Asn	gtc Val	gca Ala	gca Ala	ttc Phe	1064
55	atc Ile	atc Ile	ctc Leu	aac Asn	gac Asp	gga Gly	atc Ile	ccc Pro	atc Ile	atc Ile	tac Tyr	gcc Ala	ggc Gly	caa Gln	gaa Glu	cag Gln	1112
60	cac His	tac Tyr	gcc Ala	ggc Gly	gga Gly	aac Asn	gac Asp	ccc Pro	gcg Ala	aac Asn	cgc Arg	gaa Glu	gca Ala	acc Thr	tgg Trp	ctc Leu	1160
65	tcg Ser	ggc Gly	tac Tyr	ccg Pro	acc Thr	gac Asp	agc Ser	gag Glu	ctg Leu	tac Tyr	aag Lys	tta Leu	att Ile	gcc Ala	tcc Ser	gcg Ala	1208
70	aac Asn	gca Ala	atc Ile	cgg Arg	aac Asn	tat Tyr	gcc Ala	att Ile	agc Ser	aaa Lys	gat Asp	aca Thr	gga Gly	ttc Phe	gtg Val	acc Thr	1256
75	tac Tyr	aag Lys	aac Asn	tgg Trp	ccc Pro	atc Ile	tac Tyr	aaa Lys	gac Asp	gac Asp	aca Thr	acg Thr	atc Ile	gcc Ala	atg Met	cgc Arg	1304
80	aag Lys	ggc Gly	aca Thr	gat Asp	ggg Gly	tcg Ser	cag Gln	atc Ile	gtg Val	act Thr	atc Ile	ttg Leu	tcc Ser	aac Asn	aag Lys	ggt Gly	1352
85	gct Ala	tcg Ser	ggt Gly	gat Asp	tcg Ser	tat Tyr	acc Thr	ctc Leu	tcc Ser	ttg Leu	agt Ser	ggt Gly	gcg Ala	ggt Gly	tac Tyr	aca Thr	1400



gcc ggc cag caa ttg acg gag gtc att ggc tgc acg acc gtg acg gtt 1448  
 Ala Gly Gln Gln Leu Thr Glu Val Ile Gly Cys Thr Thr Val Thr Val  
 430 435 440 445

5 ggt tcg gat gga aat gtg cct gtt cct atg gca ggt ggg cta cct agg 1496  
 Gly Ser Asp Gly Asn Val Pro Val Pro Met Ala Gly Gly Leu Pro Arg  
 450 455 460

10 gta ttg tat ccg act gag aag ttg gca ggt agc aag atc tgt agt agc 1544  
 Val Leu Tyr Pro Thr Glu Lys Leu Ala Gly Ser Lys Ile Cys Ser Ser  
 465 470 475

15 tcg tgaaggggtgg agagtatatg atggtactgc tattcaatct ggcattggac 1597  
 Ser

agtgagtttg agtttgatgt acagttggag tcgttactgc tgatcatcccc ttatactctt 1657

20 cgattgtttt tcgaacccta atgccaagca cgctagtcta ttataggaaa aaaaaaaaaa 1717  
 aaaaaaaaaa aaaaaaa 1734

25 <210> 2  
 <211> 498  
 <212> PRT  
 <213> *Aspergillus oryzae*

30 <400> 2  
 Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln Val Ala Ala  
 -20 -15 -10 -5

35 Pro Ala Leu Ala Ala Thr Pro Ala Asp Trp Arg Ser Gln Ser Ile Tyr  
 -1 1 5 10

40 Phe Leu Leu Thr Asp Arg Phe Ala Arg Thr Asp Gly Ser Thr Thr Ala  
 15 20 25

45 Thr Cys Asn Thr Ala Asp Gln Lys Tyr Cys Gly Gly Thr Trp Gln Gly  
 30 35 40

50 Ile Ile Asp Lys Leu Asp Tyr Ile Gln Gly Met Gly Phe Thr Ala Ile  
 45 50 55 60

Trp Ile Thr Pro Val Thr Ala Gln Leu Pro Gln Thr Thr Ala Tyr Gly  
 65 70 75

55 Asp Ala Tyr His Gly Tyr Trp Gln Gln Asp Ile Tyr Ser Leu Asn Glu  
 80 85 90

60 Asn Tyr Gly Thr Ala Asp Asp Leu Lys Ala Leu Ser Ser Ala Leu His  
 95 100 105

65 Glu Arg Gly Met Tyr Leu Met Val Asp Val Val Ala Asn His Met Gly  
 110 115 120

Tyr Asp Gly Ala Gly Ser Ser Val Asp Tyr Ser Val Phe Lys Pro Phe  
 125 130 135 140

70 Ser Ser Gln Asp Tyr Phe His Pro Phe Cys Phe Ile Gln Asn Tyr Glu

	145	150	155
5	Asp Gln Thr Gln Val Glu Asp Cys Trp Leu Gly Asp Asn Thr Val Ser 160 165 170		
10	Leu Pro Asp Leu Asp Thr Thr Lys Asp Val Val Lys Asn Glu Trp Tyr 175 180 185		
15	Asp Trp Val Gly Ser Leu Val Ser Asn Tyr Ser Ile Asp Gly Leu Arg 190 195 200		
20	Ile Asp Thr Val Lys His Val Gln Lys Asp Phe Trp Pro Gly Tyr Asn 205 210 215 220		
25	Lys Ala Ala Gly Val Tyr Cys Ile Gly Glu Val Leu Asp Gly Asp Pro 225 230 235		
30	Ala Tyr Thr Cys Pro Tyr Gln Asn Val Met Asp Gly Val Leu Asn Tyr 240 245 250		
35	Pro Ile Tyr Tyr Pro Leu Leu Asn Ala Phe Lys Ser Thr Ser Gly Ser 255 260 265		
40	Met Asp Asp Leu Tyr Asn Met Ile Asn Thr Val Lys Ser Asp Cys Pro 270 275 280		
45	Asp Ser Thr Leu Leu Gly Thr Phe Val Glu Asn His Asp Asn Pro Arg 285 290 295 300		
50	Phe Ala Ser Tyr Thr Asn Asp Ile Ala Leu Ala Lys Asn Val Ala Ala 305 310 315		
55	Phe Ile Ile Leu Asn Asp Gly Ile Pro Ile Ile Tyr Ala Gly Gln Glu 320 325 330		
60	Gln His Tyr Ala Gly Gly Asn Asp Pro Ala Asn Arg Glu Ala Thr Trp 335 340 345		
65	Leu Ser Gly Tyr Pro Thr Asp Ser Glu Leu Tyr Lys Leu Ile Ala Ser 350 355 360		
70	Ala Asn Ala Ile Arg Asn Tyr Ala Ile Ser Lys Asp Thr Gly Phe Val 365 370 375 380		
	Thr Tyr Lys Asn Trp Pro Ile Tyr Lys Asp Asp Thr Thr Ile Ala Met 385 390 395		
	Arg Lys Gly Thr Asp Gly Ser Gln Ile Val Thr Ile Leu Ser Asn Lys 400 405 410		
	Gly Ala Ser Gly Asp Ser Tyr Thr Leu Ser Leu Ser Gly Ala Gly Tyr 415 420 425		

Thr Ala Gly Gln Gln Leu Thr Glu Val Ile Gly Cys Thr Thr Val Thr  
 430 435 440

5 Val Gly Ser Asp Gly Asn Val Pro Val Pro Met Ala Gly Gly Leu Pro  
 445 450 455 460

10 Arg Val Leu Tyr Pro Thr Glu Lys Leu Ala Gly Ser Lys Ile Cys Ser  
 465 470 475

Ser Ser

15

<210> 3

<211> 30

<212> DNA

20 <213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

25 <223> Primer

<400> 3

30 gaatgacttg gttgacgcgt caccagtcac

30

<210> 4

<211> 30

<212> DNA

35 <213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

40 <223> Primer

<400> 4

45 atgggttcatt tcagaactga cattgagtaa

30

<210> 5

<211> 27

<212> DNA

50 <213> Artificial/Unknown

<220>

<221> misc\_feature

<222> ()..()

55 <223> Primer

<400> 5

60 ttctgtttca tttcgaacta tgaagat

27

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

Attorney's Docket Number:  
**5835.200-US**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Fungamyl-like Alpha-Amylase Variants

The specification of which (check only one item below):

☐ is attached hereto

☒ was filed as United States application

Application No. To Be Assigned

on November 9, 2000

and was amended

on \_\_\_\_\_

☐ was filed as PCT international application

Number \_\_\_\_\_

on \_\_\_\_\_

and was amended under PCT Article 19

on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by an amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 of any provisional or foreign application(s) for patent or inventor's certificate or of any PCT international applications(s) for patent or inventor's certificate or of any PCT international applications(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR U.S. PROVISIONAL/FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119.**

COUNTRY (if PCT, indicated "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Denmark	PA 1999 01617	November 10, 1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
US	60/165786	November 16, 1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

Attorney's Docket Number:

**5835.200-US**

I hereby claim the benefit under Title 35, United States Code '120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this applications is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, '112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, '1 56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U S APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT  
UNDER 35 U.S.C. 120:

U.S. APPLICATIONS		STATUS (Check one)		
U S APPLICATION NUMBER	U.S. FILING DATE	Patented	Pending	Abandoned

PCT APPLICATIONS DESIGNATING THE U.S.				
APPLICATION NO.	FILING DATE	US SERIAL NUMBERS ASSIGNED (if any)		

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Steve T. Zelson Elias J. Lambiris Valeta A. Gregg Carol E. Rozek Robert L. Starnes Reza Green, Reg. No. 30,335 Reg. No. 33,728 Reg. No. 35,127 Reg. No. 36,993 Reg. No. 41,324 Reg. No. 38,475

Send Correspondence to: Steve T. Zelson, Esq. Or Elias J. Lambiris, Esq. [select one]  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, New York 10174-6400

Direct Telephone Calls To:  
Steve T. Zelson  
(212) 867-0123

1	Full Name of Inventor	<b>Family Name</b> <b>Bisgård-Frantzen</b>	<b>First Given Name</b> <b>Henrik</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b> <b>DK-2880 Bagsværd</b>	<b>State or Foreign Country</b> <b>Denmark</b>	<b>Country of Citizenship</b> <b>Denmark</b>
	Post Office Address	<b>Post Office Address</b> <b>Elmevænget 8B</b>	<b>City</b> <b>DK-2880 Bagsværd</b>	<b>State &amp; Zip Code/Country</b> <b>Denmark</b>
2	Full Name of Inventor	<b>Family Name</b> <b>Svendsen</b>	<b>First Given Name</b> <b>Allan</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b> <b>DK-2970 Hørsholm</b>	<b>State or Foreign Country</b> <b>Denmark</b>	<b>Country of Citizenship</b> <b>Denmark</b>
	Post Office Address	<b>Post Office Address</b> <b>Overdamsvej 13</b>	<b>City</b> <b>DK-2970 Hørsholm</b>	<b>State &amp; Zip Code/Country</b> <b>Denmark</b>
3	Full Name of Inventor	<b>Family Name</b> <b>Pedersen</b>	<b>First Given Name</b> <b>Sven</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b> <b>DK-2820 Gentofte</b>	<b>State or Foreign Country</b> <b>Denmark</b>	<b>Country of Citizenship</b> <b>Denmark</b>
	Post Office Address	<b>Post Office Address</b> <b>Emil Reesens Vej 9</b>	<b>City</b> <b>DK-2820 Gentofte</b>	<b>State &amp; Zip Code/Country</b> <b>Denmark</b>
4	Full Name of Inventor	<b>Family Name</b>	<b>First Given Name</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b>	<b>State or Foreign Country</b>	<b>Country of Citizenship</b>
	Post Office Address	<b>Post Office Address</b>	<b>City</b>	<b>State &amp; Zip Code/Country</b>

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

Attorney's Docket Number:

**5835.200-US**

5	Full Name of Inventor	<b>Family Name</b>	<b>First Given Name</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b>	<b>State or Foreign Country</b>	<b>Country of Citizenship</b>
	Post Office Address	<b>Post Office Address</b>	<b>City</b>	<b>State &amp; Zip Code/Country</b>
6	Full Name of Inventor	<b>Family Name</b>	<b>First Given Name</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b>	<b>State or Foreign Country</b>	<b>Country of Citizenship</b>
	Post Office Address	<b>Post Office Address</b>	<b>City</b>	<b>State &amp; Zip Code/Country</b>
7	Full Name of Inventor	<b>Family Name</b>	<b>First Given Name</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b>	<b>State or Foreign Country</b>	<b>Country of Citizenship</b>
	Post Office Address	<b>Post Office Address</b>	<b>City</b>	<b>State &amp; Zip Code/Country</b>
8	Full Name of Inventor	<b>Family Name</b>	<b>First Given Name</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b>	<b>State or Foreign Country</b>	<b>Country of Citizenship</b>
	Post Office Address	<b>Post Office Address</b>	<b>City</b>	<b>State &amp; Zip Code/Country</b>
9	Full Name of Inventor	<b>Family Name</b>	<b>First Given Name</b>	<b>Second Given Name</b>
	Residence & Citizenship	<b>City</b>	<b>State or Foreign Country</b>	<b>Country of Citizenship</b>
	Post Office Address	<b>Post Office Address</b>	<b>City</b>	<b>State &amp; Zip Code/Country</b>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

<b>Signature of Inventor 1</b>	<b>Signature of Inventor 2</b>	<b>Signature of Inventor 3</b>
<b>Date</b>	<b>Date</b>	<b>Date</b>
<b>Signature of Inventor 4</b>	<b>Signature of Inventor 5</b>	<b>Signature of Inventor 6</b>
<b>Date</b>	<b>Date</b>	<b>Date</b>
<b>Signature of Inventor 7</b>	<b>Signature of Inventor 8</b>	<b>Signature of Inventor 9</b>
<b>Date</b>	<b>Date</b>	<b>Date</b>